Home ›
Breast Cancer Trials ›
NCT06810804
A Phase IIa Study to Evaluate NBQ72S
A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.
Trial Details
NCT ID NCT06810804
Phase PHASE2
Sponsor Nantong Bencao Quadriga Medical Technology Co. Ltd.
Status RECRUITING
Cancer Type Breast Cancer
Interventions
Locations (sample) Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
The patient must have histological evidence confirming the diagnosis of breast cancer with leptomeningeal metastasis: a. Breast cancer must be diag… The patient's Karnofsky Performance Status (KPS) must be ≥60. The patient must have adequate bone marrow function, including: Absolute neutrophil count (ANC) ≥1,500/mm³ or ≥1.5 x 10⁹/L;
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →